Modality
Peptide
MOA
Menini
Target
EZH2
Pathway
Angiogenesis
Rett
Development Pipeline
Preclinical
~Aug 2009
→ ~Nov 2010
Phase 1
~Feb 2011
→ ~May 2012
Phase 2
~Aug 2012
→ ~Nov 2013
Phase 3
~Feb 2014
→ ~May 2015
NDA/BLA
~Aug 2015
→ ~Nov 2016
Approved
Feb 2017
→ Mar 2031
ApprovedCurrent
NCT04962343
175 pts·Rett
2023-02→2028-12·Terminated
NCT07712666
1,577 pts·Rett
2017-02→2031-03·Terminated
NCT04770434
2,369 pts·Rett
2018-09→2025-01·Not yet recruiting
4,121 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2025-01-201.2y agoPh3 Readout· Rett
2028-12-112.7y awayPh3 Readout· Rett
2031-03-135.0y awayPh3 Readout· Rett
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Approved
Termina…
Approved
Not yet…
Approved
Termina…
Catalysts
Ph3 Readout
2025-01-20 · 1.2y ago
Rett
Ph3 Readout
2028-12-11 · 2.7y away
Rett
Ph3 Readout
2031-03-13 · 5.0y away
Rett
TerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04962343 | Approved | Rett | Terminated | 175 | HbA1c |
| NCT07712666 | Approved | Rett | Terminated | 1577 | BodyWt |
| NCT04770434 | Approved | Rett | Not yet recr... | 2369 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 | |
| SLD-1824 | Solid Bio | Phase 2 | EZH2 | |
| TXG-6755 | 10x Genomics | Approved | CD123 | |
| Zoricapivasertib | CSL Limited | Phase 2 | HER2 |